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Regulation of Mucosal Addressin Cell Adhesion
Molecule 1 Expression in Human and Mice by
Vascular Adhesion Protein 1 Amine Oxidase Activity
Evaggelia Liaskou,1 Marika Karikoski,2 Gary M. Reynolds,1 Patricia F. Lalor,1 Chris J. Weston,1 Nick Pullen,5
Marko Salmi,2,4,6 Sirpa Jalkanen,2,3,6 and David H. Adams1
Primary sclerosing cholangitis (PSC) and autoimmune hepatitis are hepatic complications
associated with inﬂammatory bowel disease (IBD). The expression of mucosal addressin
cell adhesion molecule 1 (MAdCAM-1) on mucosal endothelium is a prerequisite for the
development of IBD, and it is also detected on the hepatic vessels of patients with liver dis-
eases associated with IBD. This aberrant hepatic expression of MAdCAM-1 results in the
recruitment of effector cells initially activated in the gut to the liver, in which they drive
liver injury. However, the factors responsible for the aberrant hepatic expression of MAd-
CAM-1 are not known. In this study, we show that deamination of methylamine (MA) by
vascular adhesion protein 1 (VAP-1) [a semicarbazide-sensitive amine oxidase (SSAO)
expressed in the human liver] in the presence of tumor necrosis factor a induces the expres-
sion of functional MAdCAM-1 in hepatic endothelial cells and in intact human liver tissue
ex vivo. This is associated with increased adhesion of lymphocytes from patients with PSC
to hepatic vessels. Feeding mice MA, a constituent of food and cigarette smoke found in
portal blood, led to VAP-1/SSAO–dependent MAdCAM-1 expression in mucosal vessels in
vivo. Conclusion: Activation of VAP-1/SSAO enzymatic activity by MA, a constituent of
food and cigarette smoke, induces the expression of MAdCAM-1 in hepatic vessels and
results in the enhanced recruitment of mucosal effector lymphocytes to the liver.
This could be an important mechanism underlying the hepatic complications of IBD.
(HEPATOLOGY 2011;53:661-672)
M
ucosal addressin cell adhesion molecule 1
(MAdCAM-1) is a 60-kDa endothelial cell
adhesion molecule that is constitutively
expressed on high endothelial venules (HEVs) in
Peyer’s patches (PPs) and mesenteric lymph nodes
(MLNs) and in vessels of the lamina propria.1-3
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MAdCAM-1 orchestrates the recruitment of lympho-
cytes into mucosal tissues via interactions with the
a4b7 integrin,4 and it has been implicated in the sus-
tained destructive gut inﬂammation that characterizes
inﬂammatory bowel disease (IBD).3 Its importance has
been highlighted by the fact that antibodies directed
against either MAdCAM-1 or a4b7 attenuate inﬂam-
mation in animal models and patients with colitis5,6 or
Crohn’s disease.7,8
MAdCAM-1 was initially thought to be a gut-spe-
ciﬁc molecule3 but was subsequently found to be
induced in the adult human liver in association with
portal tract inﬂammation,9 in which it could support
the adhesion of a4b7þ gut-derived lymphocytes.10
This aberrant hepatic expression of MAdCAM-1 led
to the hypothesis that an enterohepatic circulation of
long-lived mucosal lymphocytes through the liver
could trigger extra-intestinal hepatic inﬂammation in
patients with liver diseases complicating IBD.11
Another molecule potentially involved in this enter-
ohepatic lymphocyte recirculation is vascular adhesion
protein 1 (VAP-1), an adhesion molecule with amine
oxidase activity that supports lymphocyte recruitment
to the liver.12-14 Substrates for VAP-1 include aliphatic
amines such as methylamine (MA), which can be
detected in portal blood as a result of food consump-
tion.15 VAP-1 is normally expressed in the human
liver and weakly on mucosal vessels; however, it is rap-
idly induced in inﬂamed mucosa in patients with
IBD.16 Thus, there is complementarity of expression
of VAP-1 and MAdCAM-1 molecules. Moreover, pre-
vious reports from our group have shown that deami-
nation of benzylamine by the enzymatic activity of
VAP-1 on hepatic endothelium leads to nuclear factor
kappa B (NF-jB) activation, increased adhesion mole-
cule expression, and enhanced leukocyte adhesion.17
Many studies also support the role of tumor necrosis
factor a (TNF-a) in inducing MAdCAM-1 expres-
sion,18-20 and because of the colocalization of VAP-1
and MAdCAM-1 on hepatic endothelium and the
association of primary sclerosing cholangitis (PSC)
with IBD, we hypothesized that TNF-a released from
the inﬂamed gut together with increased levels of MA
in portal blood could act via VAP-1/semicarbazide-
sensitive amine oxidase (SSAO) activity to induce he-
patic MAdCAM-1 expression. Using two in vitro
human models and in vivo studies in mice, we now
show that this is the case. We suggest that this is a
novel mechanism explaining aberrant hepatic MAd-
CAM-1 expression in patients with IBD and thus an
important pathogenic mechanism in liver diseases
complicating IBD.
Materials and Methods
Human Tissue and Blood
Human liver tissue was obtained through the Liver
Unit of Queen Elizabeth Hospital. Diseased tissue
came from explanted livers removed at transplantation.
Nondiseased liver tissue came from either surplus do-
nor tissue (i.e., tissue exceeding transplantation
requirements) or surgical resections of liver tissue con-
taining metastatic tumors; in the latter case, unin-
volved tissue was taken several centimeters away from
any tumor deposits. Whole blood was obtained from
patients with PSC and IBD. All human tissue and
blood samples were collected with the approval of the
local research ethics committee and with patient
consent.
Isolation and Culture of Human Hepatic Endo-
thelial Cells (HECs). HECs were isolated from 150 g
of tissue as previously described.14 Brieﬂy, liver tissue
was digested enzymatically with collagenase type 1A
(Sigma), ﬁltered, and further puriﬁed via density gradi-
ent centrifugation over 33%/77% Percoll (Amersham
Biosciences). HECs were extracted from the mixed
nonparenchymal population initially via negative mag-
netic selection with HEA-125 (50 lg/mL; Progen Bio-
technik) to deplete biliary epithelial cells, and this was
followed by positive selection with an anti-CD31 anti-
body conjugated to Dynabeads (10 lg/mL; Invitrogen,
United Kingdom). CD31þ endothelial cells were main-
tained after isolation in rat tail collagen–coated ﬂasks
(Sigma) in complete endothelial media (Gibco, Invitro-
gen, United Kingdom) supplemented with 10% heat-
inactivated human AB serum (Invitrogen, United King-
dom) and with 10 ng/mL hepatocyte growth factor
and 10 ng/mL vascular endothelial growth factor (both
from PeproTech). HECs were grown until conﬂuency
and were used within ﬁve passages. The majority of
cells isolated by this method expressed markers of sinu-
soidal endothelium, such as liver/lymph node–speciﬁc
intercellular adhesion molecule 3–grabbing non-integ-
rin and lymphatic vessel endothelial receptor 1.21
In order to determine whether HECs have charac-
teristics consistent with vessels seen in the inﬂamed
liver, we studied the expression of endothelial adhesion
molecules with a cell-based enzyme-linked immunosor-
bent assay in HECs from normal (n ¼ 3) and diseased
livers (n ¼ 3) according to the standard methodol-
ogy.14 The protocol and antibodies are listed in the
Supporting Information Materials and Methods and
Supporting Information Table 1. The expression of cy-
tokeratin 19 (biliary epithelial cells), cytokeratin 18
(hepatocytes), CD68 (macrophages), and CD11c (den-
dritic cells) markers was used along with CD31
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(endothelial cell marker) to conﬁrm the purity of
HEC cultures by ﬂow cytometry. The antibodies are
presented in the Supporting Information Materials and
Methods and Supporting Information Table 2.
Isolation of Peripheral Blood Lymphocytes
(PBLs). Peripheral venous blood from PSC patients
with IBD was collected into ethylene diamine tetraace-
tic acid tubes, and lymphocytes were isolated by den-
sity gradient centrifugation over Lymphoprep (Sigma)
according to the established methodology.22
Cell Lines and Culture Conditions
JY cells (a B-lymphoblastoid cell line expressing
a4b7) were grown in Roswell Park Memorial Institute
1640 medium (Invitrogen) containing l-glutamine and
10% fetal bovine serum (FBS; Invitrogen).
VAP-1–Dependent MAdCAM-1 Expression
Adenoviral Infection of Human HECs With VAP-1
Constructs. Adenoviral constructs encoding wild-type
(WT) human vascular adhesion protein 1 (hVAP-1) and
enzymatically inactive hVAP-1 [Tyr(Y)471Phe(F)] have
been previously described.23 Before their use, the enzy-
matic activity of VAP-1 transfectants was conﬁrmed with
the Amplex UltraRed method, which is described in the
Supporting Information Materials and Methods. HECs
were cultured until conﬂuency, washed in phosphate-buf-
fered saline to ensure the complete removal of human se-
rum, and infected with the constructs at an optimal mul-
tiplicity of infection of 600 for 4 hours in endothelial
basal medium 2 (Clonetics, Lonza) supplemented with
10% FBS. Transfected cells were then incubated with
TNF-a (20 ng/mL; Peprotech) alone or in combination
with MA (50 lM; Sigma-Aldrich) for 2 hours.
HEC Stimulation With End Products Released
From MA Deamination by VAP-1/SSAO. Formalde-
hyde (HCHO), ammonia (NH3), and hydrogen per-
oxide (H2O2) are produced during the VAP-1–cata-
lyzed deamination of MA. In order to determine
whether these end products had a role in the induction
of MAdCAM-1, untransfected HECs were exposed to
1 or 10 lM H2O2 (BDH Prolabo), NH3 (Merck; 8
M), or HCHO (J.T. Baker; 13.44 M) for 4 hours. In
certain experiments, HECs were subjected to repeated
dosing with H2O2 (8 times at 10 lM with 30-minute
intervals) or to a combination of all three compounds,
and their effect on MAdCAM-1 messenger RNA
(mRNA) expression was analyzed. Viability assays con-
ﬁrmed that these treatments did not signiﬁcantly alter
endothelial viability after 4 hours of treatment.
Humanized VAP-1 Mice: VAP-1–Dependent Sig-
naling In Vivo. WT mice and VAP-1–deﬁcient mice
(C57BL/6) expressing enzymatically active or inactive
hVAP-1 on the endothelial cells under the control of
the mouse tie 1 promoter have been described,24 and
they were used to study the role of VAP-1 in MAd-
CAM-1 induction in vivo. All mice were handled in
accordance with the institutional animal care policy of
the University of Turku.
MA [0.4% (wt/vol)] was administered in the drink-
ing water of the animals (freshly made every day) for
14 days. After the mice were sacriﬁced, tissue samples
from PPs and MLNs were excised and used for protein
and RNA analysis.
Precision-Cut Liver Slice Organ Culture
In order to study MAdCAM-1 induction in the
intact human liver, we used a Krumdieck tissue slicer
(TCS Biologicals) to cut aseptic, 250-lm-thick slices
of live liver tissue, which could be studied for up to
48 hours ex vivo. The liver tissue was incubated in
Williams’ E media (Sigma) supplemented with 2%
FBS, 0.1lM dexamethasone (Sigma), and 0.5lM insu-
lin (Novo-Nordisk). Tissues were stimulated with MA
(50 lM) and enzymatically active recombinant vascu-
lar adhesion protein 1 (rVAP-1) produced in Chinese
hamster ovary cells (500 ng/mL; Biotie Therapies,
Turku, Finland) before MAdCAM-1 protein and RNA
analysis. The viability of the excised tissue slices was
tested with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay (Sigma) before
and after the stimulation period (details are provided
in the Supporting Information Materials and
Methods).
RNA Analysis
Total RNA was extracted with the RNeasy mini Kit
(Qiagen, United Kingdom) and analyzed as described
in the Supporting Information Materials and Methods.
Protein Analysis
MAdCAM-1 protein expression was determined by
western blotting and immunoprecipitation techniques.
The protocols and antibodies are described in the Sup-
porting Information Materials and Methods.
Immunohistochemical Analysis
Multicolor ﬂuorescence confocal microscopy was
used to localize the expression of MAdCAM-1 in
HECs. MAdCAM-1 expression in human liver tissue
was investigated in formalin-ﬁxed, sucrose-embedded
tissues with NovaRED immunostaining. The presence
of murine MAdCAM-1 in PPs and MLNs was exam-
ined by immunoﬂuorescence. The protocols and
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antibodies are described in the Supporting Information
Materials and Methods and Supporting Information
Table 3.
Static Adhesion Assays
Formalin-ﬁxed, sucrose-embedded sections (10 lm
thick) were incubated with JY cells and PBLs from
PSC patients (n ¼ 3) for 30 minutes at room temper-
ature. In certain experiments, tissue sections were incu-
bated with an anti–MAdCAM-1 antibody (P1; 1 lg/
mL; Pﬁzer), and JY cells and PBLs were blocked with
anti-a4b7 [actin 1 (ACT-1); 1 lg/mL; a gift from M.
Briskin, Millenium, United States] for 30 minutes
before the static assays. An isotype-matched control
(IMC) antibody (immunoglobulin G1; 1 lg/mL;
Dako) was used as a negative control. After several
washes to remove unbound antibodies, sections were
incubated with 105 JY or PSC PBLs/100 lL and resus-
pended in Roswell Park Memorial Institute 1640 me-
dium plus 0.1% bovine serum albumin. Cells were
allowed to bind under static conditions at room tem-
perature for 30 minutes before they were washed, ﬁxed
in acetone, and counterstained with Mayer’s hematoxy-
lin (VWR International, Ltd.). Slides were analyzed
via the manual counting of adherent lymphocytes in
40 representative high-power ﬁelds (with a 40
objective).
Flow-Based Adhesion Assays
The function of the MAdCAM-1 protein in vitro
was studied with ﬂow-based adhesion assays.17 Brieﬂy,
conﬂuent monolayers of HECs were cultured in
microcapillaries and stimulated for 2 hours with TNF-
a and MA before the perfusion of a4b7þ JY cells at a
wall shear stress of 0.05 Pa. Adherent cells were visual-
ized by phase contrast microscopy (with a 10 objec-
tive) and classiﬁed as rolling, static, or migrated cells.
The total adhesion was calculated as cells per square
millimeter normalized to the number of perfused lym-
phocytes. In function-blocking experiments, HECs
were pretreated with a humanized anti-human P1 anti-
body (5 lg/mL), or JY cells were incubated with anti-
a4b7 (ACT-1; 1 lg/mL) for 30 minutes at 37C. An
IMC antibody (immunoglobulin G1; 1 lg/mL; Dako)
was used as a negative control.
Statistical Analyses
Data were analyzed with the Student t test for com-
parisons of numerical variables between two groups
and with one-way analysis of variance analysis followed
by a Bonferroni post test for comparisons between
more than two groups. Statistical analyses were per-
formed with GraphPad Prism software. P < 0.05 was
considered statistically signiﬁcant.
Results
Purity and Phenotypic Characterization of HECs
We analyzed the purity of our HEC primary cul-
tures and conﬁrmed that more than 99% of HECs
were CD31þ, with very few contaminating nonendo-
thelial cells (Supporting Information Fig. 1A). As
reported previously, HECs lack P-selectin but express
minimal levels of E-selectin, low levels of vascular cell
adhesion molecule 1 (VCAM-1), and high constitutive
levels of intercellular cell adhesion molecule 1 (ICAM-
1) and CD31, which are all increased upon inﬂamma-
tion.25 We conﬁrmed that under basal conditions,
HECs isolated from nondiseased livers (two resections
and one normal donor) and diseased livers [one with
PSC, one with primary biliary cirrhosis (PBC), and
one with alcoholic liver disease (ALD)] adopted a non-
activated phenotype expressing similarly high levels of
ICAM-1 and CD31, low levels of VCAM-1 and E-
selectin, and no P-selectin (Supporting Information
Fig. 1B). Thus, in this study, we grouped together the
data from all HECs used.
Treatment of HECs With the VAP-1/SSAO
Substrate MA and TNF-a Induces MAdCAM-1
mRNA Expression, Protein Redistribution Onto
the Cell Surface, and Increased Secretion of
Soluble Mucosal Addressin Cell Adhesion Molecule
1 (sMAdCAM-1)
Using quantitative polymerase chain reaction
(PCR), we detected signiﬁcantly higher MAdCAM-1
mRNA levels in HECs stimulated with TNF-a alone
and in combination with MA versus unstimulated
HECs (Fig. 1A). Total cell MAdCAM-1 protein levels
were unaffected by stimulation, and no detectable
increase in cytoplasmic MAdCAM-1 was observed ei-
ther; this was conﬁrmed by western blotting and ﬂow
cytometry (data not shown). However, using live cell
staining and confocal microscopy, we observed that the
MAdCAM-1 protein was redistributed onto the sur-
face of HECs stimulated with TNF-a and MA (Fig.
1B). In addition, we found that MAdCAM-1 was
released in a soluble form (sMAdCAM-1) in the su-
pernatant of TNF-a–treated and MA-treated HECs in
comparison with media alone (Fig. 1C). Therefore, we
have shown that MA and TNF-a up-regulate MAd-
CAM-1 mRNA expression in HECs, induce protein
redistribution onto the cell surface, and promote
increased secretion of sMAdCAM-1.
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MAdCAM-1 Expressed by HECs Is
Functionally Active
To study the function of HEC-expressed MAdCAM-1,
we used ﬂow-based adhesion assays with JY cells, which
express high levels of the MAdCAM-1 receptor a4b7
on the cell surface (Fig. 2A). JY cells were perfused over
HEC monolayers at 0.05 Pa, and adhesion was
recorded. Under basal conditions, no adhesion was
detected; however, stimulation of HECs with TNF-a
and MA signiﬁcantly increased the total number of ad-
herent cells, and this was reduced by an antibody block-
ade of MAdCAM-1 (P1) or a4b7 (ACT-1; Fig. 2B).
The IMC antibody that was used showed no inhibitory
effect [109 6 21 adherent cells/mm2/106 perfused cells
(standard error of the mean) in HECs treated with
TNF-a and MA and 116 6 41 adherent cells/mm2/106
perfused cells in TNF-a and MA and isotype control
stimulated HEC]. Altogether, our data show that TNF-
a and MA induce the redistribution of the MAdCAM-1
protein onto the cell surface and render it functionally
active to support the binding of a4b7þ JY cells.
VAP-1/SSAO Enzyme Activity Induces Endothelial
Expression of MAdCAM-1 In Vitro
To validate the role of VAP-1/SSAO in MAdCAM-
1 induction, we used adenoviral constructs encoding
Fig. 1. The physiological VAP-1 substrate MA potentiates TNF-a–induced expression of MAdCAM-1 in HECs. Endothelial cells were stimulated
with TNF-a (20 ng/mL), MA (50 lM), or a combination of the two for 2 hours. (A) mRNA analysis by quantitative PCR. Data represent MAdCAM-1
mRNA fold changes in stimulated HECs versus a control (no stimulation). Means and standard deviations are shown (n ¼ 7 HECs). *P < 0.05 ver-
sus the control by the Student t test. (B) Confocal microscopy images of unstimulated live HECs (control) and HECs stimulated with TNF-a and MA
(either alone or in combination). The localization of the MAdCAM-1 protein on the cell surface is shown in red. CD31 (red) was used as a positive
control, and an IMC antibody was used as a negative control. Cell nuclei were stained with 40,6-diamidino-2-phenylindole (blue). The original magni-
ﬁcation was 40. The white arrow indicates MAdCAM-1 redistribution onto the cell surface after TNF-a and MA stimulation. (C) MAdCAM-1 was
immunoprecipitated from the cell culture supernatants of the control and 2-hour–stimulated cells. sMAdCAM-1 was captured with the polyclonal
antibody (H-116), and a 60-kDa molecular weight band was detected with the monoclonal antibody (CA102.2C1). Densitometric analysis was per-
formed for six different HEC isolates. Data represent the mean percentages and standard errors of the mean of the relative intensity normalized to
the serum albumin levels and compared to the control (set to 100%). *P ¼ 0.04 versus the sMAdCAM-1 levels in the control by the Student t test.
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enzymatically active and inactive hVAP-1. The enzyme
activities of the constructs were conﬁrmed before use
(Supporting Information Fig. 2). More than 95% of
HECs transfected with the adenoviral constructs
expressed hVAP-1 on their surface (Fig. 3A), with sim-
ilar median channel ﬂuorescence values for the two
constructs (197 6 40 for hVAP-1 and 216 6 40 for
hVAP-1_Y471F, n ¼ 7 HECs). We then exposed
transfected HECs to MA and TNF-a and observed
increased MAdCAM-1 protein levels in HECs trans-
fected with enzymatically active hVAP-1 (Fig. 3B1).
Under control conditions, the presence of WT hVAP-
1 caused a signiﬁcant increase in comparison with
HECs transfected with the mutant hVAP-1, probably
as a result of endogenous ligands. When HECs were
stimulated with TNF-a and MA in the presence of
WT hVAP-1, there was a signiﬁcant increase in MAd-
CAM-1 expression in comparison with HECs trans-
fected with mutant hVAP-1 (Fig. 3B2).
To further conﬁrm the role of VAP-1/SSAO in
MAdCAM-1 induction, we studied the effects of the
end products released by MA deamination by VAP-
1. Untransfected HECs were stimulated with the
MA metabolites H2O2, NH3, and HCHO for 4
hours, at which time more than 98% of the cells
were viable (data not shown). When H2O2 was
administered repeatedly every 30 minutes at 10 lM
with the other end products, there was a signiﬁcant
10-fold increase in MAdCAM-1 expression (Fig.
3C). Therefore, our data show that the enzymatic ac-
tivity of VAP-1 can up-regulate MAdCAM-1 expres-
sion in HECs.
Fig. 2. MAdCAM-1 expressed by HECs supports lymphocyte adhesion in a ﬂow-based adhesion assay. (A) Representative ﬂow cytometry dot
plots show the coexpression of a4, b1, and CD11a with b7 integrin on JY cells. (B) HECs were treated with TNF-a (20 ng/mL) alone or in com-
bination with MA (50 lM) for 2 hours, and JY cells were perfused over the monolayer at a shear stress of 0.05 Pa. Adhesion was blocked by
function-blocking antibodies directed against MAdCAM-1 (P1; 5 lg/mL; HECs) or a4b7 (ACT-1; 1 lg/mL; JY cells). Data represent the mean ad-
hesion values and standard errors of the mean from seven different HECs. *P < 0.05, **P < 0.01, and ***P < 0.001 by the Student t test.
(C) Representative images captured from experimental videos show adherent cells in the absence and presence of function-blocking antibodies
(P1 and ACT-1) or an IMC.
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VAP-1/SSAO Induces Human Hepatic
MAdCAM-1 Expression Ex Vivo
To validate the in vitro effects of VAP-1/SSAO sig-
naling, we used a liver organ culture system in which
viable, precision-cut human liver slices were stimulated
with rVAP-1 and MA. Initially, we studied the expres-
sion of MAdCAM-1 in normal liver tissues and dis-
eased liver tissues [PBC, ALD, PSC, and autoimmune
hepatitis (AIH)] and found higher MAdCAM-1
expression levels in chronic liver diseases (Fig. 4A);
this agreed with previous reports.10 We then stimu-
lated normal liver tissue slices with rVAP-1 and its
substrate MA to see whether increased enzyme activity
would induce MAdCAM-1 expression. Time course
studies detected increased MAdCAM-1 protein expres-
sion, which peaked at 4 hours; this was followed by a
decline until 8 hours of treatment (Fig. 4B). rVAP-1
and MA caused a signiﬁcant increase in MAdCAM-1
mRNA levels in normal liver tissue (n ¼ 4; Fig. 4C)
and increased MAdCAM-1 protein expression in
Fig. 3. VAP-1/SSAO induces MAdCAM-1 expression in vitro. (A) HECs were transfected with adenoviral constructs expressing WT hVAP-1 or an
enzymatically inactive mutant of hVAP-1 (hVAP-1_Y471F). VAP-1 positivity on transfected HECs was conﬁrmed by ﬂow cytometry with anti–VAP-1 or
negative control mouse anti-human antibodies. Data are representative of seven different HECs. (B) After adenoviral transfection, HECs were stimu-
lated with TNF-a (20 ng/mL) or MA (50 lM) for 2 hours before lysis and western blotting: (1) representative blots of the 120-kDa MAdCAM-1 di-
meric protein and 40-kDa b-actin and (2) densitometric analysis of seven different HECs. Data represent the mean percentages and standard errors
of the mean of the MAdCAM-1 protein expression normalized to endogenous b-actin levels and are shown with respect to the expression in unstimu-
lated (control) HECs transfected with mutant hVAP-1 (HECþhVAP-1_Y471F; set to 100%). Statistical analysis was performed with the Student t test.
*P ¼ 0.021 versus control HECþhVAP-1_Y471F and **P ¼ 0.005 versus HECþhVAP-1_Y471F stimulated with TNF-a and MA. (C) End products of
VAP-1 enzyme activity induced MAdCAM-1 expression by HECs. Untransfected HECs were stimulated with single doses of H2O2, HCHO, and NH3 at 1
or 10 lM for 4 hours. As indicated, HECs were treated repeatedly with 10 lM H2O2 (8 times every 30 minutes; 10  8) or with a combination of
all three end products (each at 1 or 10 lM single doses and H2O2 added repeatedly). RNA was extracted from cells, and MAdCAM-1 mRNA expres-
sion was measured with quantitative PCR. Data represent the relative expression of treated HECs versus untreated HECs (the mean is shown as a
horizontal line; the data were taken from nine different HECs). *P ¼ 0.04 versus the control by one-way analysis of variance.
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vessels (Fig. 4D). An MTT assay also revealed >91%
viability after 4 hours of stimulation (data not shown).
To show that the induced MAdCAM-1 was functional,
we used static adhesion assays, and we demonstrated
increased a4b7þ JY cell binding to hepatic vessels in
tissues stimulated with rVAP-1 and MA (Fig. 5A); this
was reduced by the pretreatment of tissues with an
anti–MAdCAM-1 antibody (P1) or lymphocytes with
a4b7 (Fig. 5C,E). We then conﬁrmed the ﬁndings
with PBLs from PSC patients with IBD; these cells
adhered efﬁciently to tissues stimulated with rVAP-1
and MA (Fig. 5B), and again, this was blocked by
anti–MAdCAM-1 (P1) and anti-a4b7 (ACT-1; Fig.
5D). The IMC antibody did not cause any reduction
in adhesion (Fig. 5C,D). Thus, these data conﬁrm that
VAP-1/SSAO can induce the expression of functionally
active human hepatic MAdCAM-1 ex vivo, which is
able to regulate lymphocyte recruitment to the liver.
VAP-1/SSAO Induces MAdCAM-1
Expression In Vivo
To investigate the role of VAP-1/SSAO–dependent
MA deamination in MAdCAM-1 expression in vivo, we
used WT mice and VAP-1–deﬁcient mice expressing
hVAP-1 in an enzymatically active or inactive form as a
transgene in endothelial cells. The presence of hVAP-1
in the livers of transgenic animals was conﬁrmed by im-
munoﬂuorescent staining (Fig. 6A). To test whether MA
could alter MAdCAM-1 expression in vivo, it was given
Fig. 4. MAdCAM-1 is expressed in the diseased human liver, and expression is increased in the normal liver (NL) by VAP-1/SSAO activity ex
vivo. (A) MAdCAM-1 mRNA expression in NL (n ¼ 3), PBC (n ¼ 3), ALD (n ¼ 3), AIH (n ¼ 3), and PSC (n ¼ 9) tissues: MAdCAM-1 mRNA lev-
els (means and standard deviations) in diseased livers with respect to NL tissues (the mean is shown as a horizontal line). *P < 0.05 and **P
< 0.01 versus expression in NL by the unpaired Student t test. (B) NL tissue slices were stimulated with rVAP-1 (500 ng/mL) and MA (50 lM)
for 0 to 8 hours, and the MAdCAM-1 protein was analyzed by western blotting. Data represent the percentage of MAdCAM-1 protein expression
normalized to the endogenous b-actin levels. (C) Precision-cut NL tissue slices (250 lm) from four different livers were stimulated with MA and
rVAP-1 for 4 hours, and MAdCAM-1 mRNA expression was analyzed by quantitative PCR. MAdCAM-1 mRNA fold changes in treated samples ver-
sus control samples are shown. *P < 0.05 versus the control by the Student t test. (D) MAdCAM-1 protein expression in vessels and sinusoids
(black arrows) on a representative untreated NL (control) or an NL stimulated with MA and rVAP-1. The original magniﬁcation was 600.
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to the animals through their drinking water for 14 days.
We were unable to detect MAdCAM-1 mRNA or pro-
tein in the murine liver before or after stimulation in all
animal models by mRNA analysis, western blotting, and
immunoﬂuorescence (data not shown). However, we
detected signiﬁcant 10- and 16-fold increases in MAd-
CAM-1 mRNA levels and increased MAdCAM-1 pro-
tein levels in PPs and MLNs of transgenic animals
expressing enzymatically active hVAP-1 after MA admin-
istration (Fig. 6A,B). The importance of VAP-1/SSAO
in this induction was conﬁrmed by studies showing
reduced MAdCAM-1 mRNA induction in mice express-
ing the enzymatically inactive form of hVAP-1 (Fig.
6B). Therefore, these data demonstrate the ability of
VAP-1 enzyme activity to induce MAdCAM-1 expres-
sion in gut mucosal vessels in vivo.
Discussion
The ability of aberrantly expressed hepatic MAd-
CAM-1 to recruit mucosal T cells to the liver in
patients with PSC9,10 led us to further investigate
Fig. 5. MAdCAM-1 induced in the normal liver supports the adhesion of JY cells and PBLs from PSC patients. Static adhesion assays show the
adhesion of (A) a4b7þ JY cells and (B) PBLs from PSC patients to normal liver sections cut from precision-cut liver slices after 4 hours of stimula-
tion with rVAP-1 and MA. Data represent the mean adhesion values and standard errors of the mean from four normal livers and three PSC PBLs.
(C,D) Binding was inhibited when MAdCAM-1 (P1; 1 lg/mL) and a4b7 (ACT-1; 1 lg/mL) were blocked. Data show the percentage of adherent
cells versus control samples; when blocking was used, data show the percentage of adherent cells versus adhesion in samples for which no anti-
body was used (No Ab). An IMC was used at 1 lg/mL. *P < 0.01, **P < 0.01, and ***P < 0.001 by the Student t test. (E) Representative im-
munostaining pictures show adherent lymphocytes in rVAP-1–stimulated and MA-stimulated normal liver tissue and nonadhering lymphocytes in
tissues in which MAdCAM-1 was blocked (P1). Images were acquired at the original magniﬁcations of 600 and 400, respectively.
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factors involved in hepatic MAdCAM-1 induction. In
this study, we provide evidence that VAP-1/SSAO–de-
pendent oxidation of MA increases MAdCAM-1
expression in HECs in vitro and ex vivo and in muco-
sal vessels in vivo. These ﬁndings implicate VAP-1/
SSAO activity in inducing and maintaining MAd-
CAM-1 expression in the gut and the liver.
Although provision of the VAP-1 substrate MA or
TNF-a led to induction of MAdCAM-1, the combina-
tion of the stimuli had an additive effect. The role of
TNF-a in MAdCAM-1 induction has been reported
previously in both in vitro and in vivo systems.18-20
However, it is unlikely that TNF-a alone is sufﬁcient
to induce hepatic MAdCAM-1 in vivo because hepatic
MAdCAM-1 expression is limited, with the strongest
and most consistent expression seen in patients with
PSC or AIH complicating IBD.10 This led us to look
for other factors that may have a particular role in the
liver. VAP-1 is constitutively expressed in the human
liver, and we have previously reported that the enzy-
matic activity of VAP-1 generates products (including
H2O2) that can activate NF-jB–dependent adhesion
molecule expression.17 This led us to hypothesize that
the VAP-1/SSAO enzymatic activity could also pro-
mote MAdCAM-1 expression. We now conﬁrm that
this is the case, and we further demonstrate that the
natural VAP-1/SSAO substrate MA, which is present
in food, wine, and cigarette smoke, is able to increase
MAdCAM-1 expression in vitro, in vivo, and ex vivo.
Human HECs exposed to TNF-a and MA showed
increased MAdCAM-1 mRNA transcription, protein
redistribution onto the cell surface, and increased
Fig. 6. VAP-1/SSAO induces MAdCAM-1 expression in vivo. WT mice and VAP-1–deﬁcient mice expressing enzymatically active (VAP-1_EA)
and inactive (VAP-1_EI) hVAP-1 were supplied with 0.4% (wt/vol) MA (MAþ) in their drinking water for 14 days. WT mice without MA treatment
were used as controls (WT_MA). (A) Immunoﬂuorescent staining of MAdCAM-1 in HEVs (white arrows) of PPs and MLNs and in vivo expression
of hVAP-1 in the livers of transgenic mice. An IMC antibody was used as a negative control. (B) MAdCAM-1 mRNA analysis with real-time PCR.
Data represent MAdCAM-1 mRNA fold changes (means and standard deviations) in PPs and MLNs in mice (n ¼ 3 in each group) receiving MA
versus WT_MA mice (n ¼ 3). *P < 0.04 in both PPs and MLNs of EA_MAþ mice versus WT_MA mice by the Student t test and *P ¼ 0.03
in MLNs of EA_MAþ mice versus EI_MAþ mice by the Student t test.
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secretion of the sMAdCAM-1 protein. Using ﬂow-
based adhesion assays, we conﬁrmed that MA/TNF-a–
induced MAdCAM-1 on HECs was functionally active
and able to support increased adhesion of a4b7-
expressing JY cells. There was residual binding of JY
cells after MAdCAM-1 or a4b7 blocking, which we
believe was mediated by lymphocyte function-associ-
ated antigen 1/ICAM-1. We also found that TNF-a
and MA stimulation induced the production of a solu-
ble form of MAdCAM-1. Leung et al.26 ﬁrst reported
sMAdCAM-1 in human serum, urine, and other bio-
logical ﬂuids, but it is not known whether this soluble
form is functional. Soluble forms of other adhesion
molecules, including E-selectin and VAP-1, have the
ability to enhance adhesion to endothelium.27,28
Therefore, sMAdCAM-1 produced via the action of
VAP-1/SSAO could also serve as an attractant increas-
ing leukocyte adhesion.
In addition to functioning as an adhesion molecule,
VAP-1 is also an enzyme, and this led us to investigate
whether this enzyme activity is critical for MAdCAM-1
induction. We present several pieces of experimental
data to support this: (1) the provision of MA and
TNF-a to HECs overexpressing enzymatically active
hVAP-1 increased MAdCAM-1 expression, whereas
HECs expressing enzymatically inactive hVAP-1 did
not respond, and (2) the treatment of HECs with the
end products of VAP-1 deamination of MA (HCHO,
NH3, and H2O2) increased MAdCAM-1 expression
10-fold. Local H2O2 has been implicated in the regula-
tion of adhesion molecule expression.29-32 We have
reported that the end products of SSAO deamination
(including H2O2) induce expression of endothelial E-
and P-selectins in vascular endothelium32 and expres-
sion of ICAM-1, VCAM-1, and chemokine (C-X-C
motif ) ligand 8 in human hepatic sinusoidal endothe-
lium through stimulation of the phosphoinositide 3-ki-
nase, mitogen-activated protein kinase, and NF-jB
pathways.17 Thus, H2O2 released as a result of MA
deamination by VAP-1 could operate through the NF-
jB binding elements present in the human MAdCAM-
1 promoter region33 to induce MAdCAM-1 expression.
The studies using primary HECs were compelling,
but we wanted to see if MA could induce functional
MAdCAM-1 in intact liver tissue. To do this, we used
a novel liver organ culture system in which we could
culture viable human liver tissue slices for up to 48
hours ex vivo. The addition of MA to cultures of nor-
mal human liver tissue resulted in VAP-1/SSAO–de-
pendent induction of MAdCAM-1 RNA and protein
on hepatic endothelium. Furthermore, we were able to
conﬁrm that the induced MAdCAM-1 was functional
because it supported the adhesion of PBLs from
patients with PSC to vessels in the tissue slices via the
a4b7 integrin, which is expressed by up to 40% of cir-
culating T cells in patients with PSC.34
Finally, we wanted to conﬁrm the ability of VAP-1/
SSAO to induce MAdCAM-1 in vivo. To do this, we
used mice but found that we were unable to detect or
induce any MAdCAM-1 in the murine liver. This ﬁnd-
ing agreed with reports from Bonder et al.,13 who failed
to detect MAdCAM-1 in murine portal venules and si-
nusoids after concanavalin A administration. This is a
clear difference between mice and humans and might
explain why it has been difﬁcult to develop a represen-
tative murine model of PSC. However, MAdCAM-1 is
expressed in mucosal vessels in mice, in which it is
increased by inﬂammation. We now report that MA
feeding increased MAdCAM-1 expression in HEVs of
PPs and MLNs, and we conﬁrmed that this induction
was dependent on the enzymatic activity of VAP-1/
SSAO because overexpression of enzymatically active en-
dothelial VAP-1 in transgenic animals led to a signiﬁ-
cant increase in MAdCAM-1, which was reduced in
animals expressing enzymatically inactive hVAP-1. Inter-
estingly, WT animals did not show consistent responses
to MA, and this probably reﬂects the relatively low lev-
els of VAP-1/SSAO present in the absence of inﬂamma-
tion. Surprisingly, increased levels of MAdCAM-1 were
detected in transgenic animals expressing enzymatically
inactive hVAP-1. Although these levels were not gener-
ally as high as those seen in mice overexpressing enzy-
matically intact hVAP-1, we suggest that VAP-1 might
also induce MAdCAM-1 by acting as an adhesion mol-
ecule and recruiting lymphocytes that then secrete fac-
tors promoting MAdCAM-1 induction.
In conclusion, our data reveal that VAP-1/SSAO
contributes to MAdCAM-1 induction in HECs in
vitro and ex vivo in humans and in gut mucosal vessels
in vivo in mice. On the basis of these ﬁndings and
previous reports describing the induction of VAP-1
during gut inﬂammation,16 we suggest that MA at
increased levels due to enhanced absorption via an
inﬂamed gut or cigarette smoke15 acts as a substrate
for VAP-1/SSAO and thus leads to MAdCAM-1
expression in the inﬂamed gut mucosa and hepatic en-
dothelium. This could promote the uncontrolled
recruitment of mucosal effector cells and result in tis-
sue damage that is characteristic of both IBD and its
hepatic complications. Thus, targeting VAP-1/SSAO
therapeutically could not only reduce lymphocyte ad-
hesion directly but could also down-regulate MAd-
CAM-1 expression and lead to the resolution of both
liver and gut inﬂammation.
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